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Abstract To better understand the detection and manage-
ment of iron overload in transfusion-dependent patients
with myelodysplastic syndromes (MDS), a 15-min web- or
paper-based survey was conducted among 338 European
physicians from 27 countries. Respondents had a mean of
18 years of clinical experience. Forty-six percent and 27%
of physicians noted that detecting and treating iron overload
were either “very important” or “important,” respectively.
The main reason for not actively exploring iron overload
was related to poor patient prognosis, while the main
reasons for not initiating iron chelation therapy were poor
patient prognosis and older patient age. Thirty-seven
percent and 31% of physicians believed that treating iron
overload in these patients was “very important” or
“important,” respectively. Ninety percent of physicians
prescribed iron chelation therapy, and 38% of transfusion-
dependent patients received iron chelation therapy. The key
reasons for not initiating iron chelation therapy were related
to poor patient prognosis (72%), patient age ≥85 years
(50%), and comorbidities (34%). The views of these
experienced MDS physicians reflect available international
MDS treatment guidelines.
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Introduction
Red blood cell (RBC) transfusions are a common therapy to
treat symptomatic anemia that affects most patients with
myelodysplastic syndromes (MDS) [1]. Several retrospec-
tive studies have shown that patients who become RBC
transfusion-dependent have a significantly shorter overall
survival than those who are not dependent on transfusions
[2, 3]. This decreased survival may in part be due to
patients accumulating excess iron and/or to intrinsically
more severe bone marrow disease than in nondependent
patients. International Prognostic Scoring System (IPSS)
Low- and Intermediate-1 (Int-1)-risk patients, who may
have prolonged survival, receive blood transfusions for
many years and may be exposed to a greater risk of iron
overload, leading to progressive dysfunction in organs such
as the liver, heart, and endocrine glands [2, 4].
Guidelines from Spain [5], the Italian Society of
Hematology [6], the UK MDS Guidelines Group [7], the
National Comprehensive Cancer Network in the USA [8],
and the MDS Foundation [4], all recommend the use of iron
chelation therapy in patients with Low- or Int-1-risk MDS
who have received more than 20 to 50 transfusions. In
Europe, these recommendations, although not based on
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DOI 10.1007/s00277-011-1181-8controlled clinical trials demonstrating superiority of iron
chelation versus observation alone, have an impact on the
perceptions and prescriptions of iron chelation therapy in
patients with MDS. There is currently some controversy
regarding the use of iron chelation therapy in these patients,
particularly because they have a median age of 70 years,
and many patients with a poor prognosis may not survive
long enough to develop the clinical consequences of iron
overload [9–11]. There is some argument, however, that
even patients with higher-risk MDS may also benefit from
iron chelation therapy through improved outcome of
allogeneic stem cell transplantation, possible decreases in
infection, and although controversial, delayed leukemic
transformation in some cases [6, 12].
In order to understand what physicians treating
transfusion-dependent patients with MDS in Europe believe
to be the reasons for their willingness or reservations
toward detecting and managing iron overload, a survey of
European physicians has been conducted. The MDS Iron-
Overload Detection Insight Survey (MIDIS) was conducted
by the MDS Foundation and the European School of
Haematology (ESH) in partnership with Novartis Oncolo-
gy. The results of the survey are presented here.
Design and methods
Inclusion/exclusion criteria
To participate in the study, respondents had to be physicians
from a European country, either fully qualified, in training
or completing their internship, and seeing at least one
transfusion-dependent patient with MDS in an average 6-
month period.
MIDIS was initiated at the 2008 meeting of the
American Society of Hematology and was also distributed
at other international conferences via e-mails, letters, and
flyers, as well as links to the survey hosted on the MDS
Foundation and ESH websites.
Study questionnaire
MIDIS was a quantitative survey that comprised up to 33
structured questions that could be completed either on
paper or online in approximately 15 min. The questions
were reviewed by a study steering committee, comprising
the authors and external experts, prior to being included in
the survey. The questions were related to profiling and
demographics of the respondents (qualification status,
primary specialty, work setting, number of transfusion-
dependent patients with MDS seen, and involvement in
MDS), detection of iron overload (frequency of serum
ferritin testing, influence of serum ferritin tests on treatment
decisions, importance of detecting iron overload, and
potential reasons for and reservations against detection),
and treatment of iron overload with chelation therapy
(importance of treatment, use of iron chelation therapy,
markers for therapy initiation, number of patients who
receive iron chelation therapy, and potential reasons for and
reservations against iron chelation therapy). Questions
relating to detection and treatment of iron overload were
answered using a scale from 1 (indicating not important at
all) to 7 (very important). Questions relating to barriers and
triggers for detecting and treating iron overload were also
answered using a scale from 1 (indicating not a barrier or
trigger at all) to 7 (a strong barrier or trigger).
Analysis
Collection and analysis of the MIDIS results were under-
taken by the HealthCare Division of GfK SE. The results
for both respondents' background, and barriers and triggers
toward detection and treatment of iron overload, were
analyzed quantitatively.
Results
Respondent demographics
A total of 338 physicians from 27 European countries
participated in the survey (Table 1). Their profile shows that
they were experienced clinicians specializing mostly in
hematology (Table 2). A total of 88% were involved in
diagnosing patients with MDS, 87% initiated treatment for
MDS, and the same proportion was involved in the
maintenance of treatment for MDS. The survey was
completed by the respondents themselves.
Detection of iron overload
On a scale from 1 (not important at all) to 7 (very
important), the majority of the respondents believed that
detection of iron overload in transfusion-dependent patients
with MDS was “very important” (score 7; 46% of
respondents) or “important” (score 6; 27%; Fig. 1). The
mean score for the subjective importance of detecting iron
overload in transfusion-dependent patients with MDS was
6.1.
On a similar 1–7 scale, most respondents believed that it
was “very likely” (score 7; 40%) or “likely” (score 6; 25%)
that iron overload would be detected at their institution
(mean score=5.8). Approximately half of the respondents
(53%) said that they monitored serum ferritin levels in their
transfusion-dependent patients every 3 months, with 26%
responding that the frequency of serum ferritin monitoring
668 Ann Hematol (2011) 90:667–673depended on the rate of transfusions that the patient was
receiving. Respondents said that in 46% of cases, the
results of serum ferritin monitoring “always” influenced
their decisions on how they treated their patients, and
“sometimes” influenced this in 47% of cases.
The factors that positively influenced detection of iron
overload included patients having received >20 RBC units
(relevant trigger in 76% of respondents), introduction of
serum ferritin as a standard test (76%), and awareness of
the potential risks of frequent transfusions (75%). On a
scale from 1 (not an aid at all) to 7 (a strong aid), the mean
scores for these factors were 6.1, 6.1, and 6.0, respectively.
The most important reasons for not detecting iron
overload were poor patient prognosis, irregular serum
ferritin monitoring, and lack of awareness about guidelines
and risks of iron overload (Fig. 2). Other reasons included a
low priority for iron-overload screening, and perceptions
about the importance of iron overload in MDS.
Respondents' opinions were polarized about whether or
not regularly monitoring serum ferritin levels was a reason
for not detecting iron overload. While 30% said that this
“strongly prevented” or “prevented” them from detecting
iron overload, a similar proportion of respondents (38%)
believed that this “did not,” or “did not at all,” prevent them
from detecting iron overload (Fig. 2).
Treatment of iron overload with iron chelation therapy
On a scale from 1 (not important at all) to 7 (very
important), respondents said that they believed that treating
iron overload in transfusion-dependent patients with MDS
was “very important” (score 7; 37% of the respondents) or
“important” (score 6; 31%); the mean score was 5.9 (Fig. 3).
The survey showed that 90% of respondents prescribed
iron chelation therapy to their transfusion-dependent
patients with MDS. Nonetheless, not all of these patients
received iron chelation therapy; out of a mean of 34
transfusion-dependent patients with MDS seen in each of
the respondents' practices or institutions in an average 6-
month period, 13 (38%) received iron chelation therapy.
The factor that most led respondents to initiate iron
chelation therapy was patient age of 55–64 years (relevant
Table 2 Respondent characteristics
Characteristic n=338
Mean age (years) 44
Male/female (n (%)) 183 (54)/155 (46)
Primary specialty (n (%))
Hematologist 312 (92)
Oncologist 8 (2)
General practitioner 4 (1)
Transfusionist 2 (0.6)
Cytogeneticist 1 (0.3)
Other physician 11 (3)
Qualification (n (%))
Fully qualified 293 (87)
In training or completing internship 45 (13)
Work place (n (%))
Teaching hospital 199 (59)
General hospital 95 (28)
Office-based, cancer center, private
hospital, or other
44 (13)
Experience as a physician, mean
number of years
a
18
<16 years of experience (n (%)) 159 (47)
≥16 years of experience (n (%)) 177 (52)
Mean number of patients with MDS
seen per month (n)
18
As a proportion of total patients seen (%) 12
Mean number of transfusion-dependent
patients with MDS seen over a
6-month period (n)
19
aTwo (1%) respondents did not answer this question
Country Responses
Austria 8
Belgium 22
Bulgaria 4
Croatia 4
Czech Republic 19
Denmark 5
Estonia 4
Finland 1
France 43
Germany 20
Greece 16
Hungary 3
Italy 39
Lithuania 1
Macedonia 6
Malta 1
Netherlands 2
Norway 2
Poland 11
Portugal 9
Romania 6
Serbia 1
Slovakia 19
Spain 45
Sweden 4
Switzerland 7
UK 36
Total 338
Table 1 Countries represented
in the survey
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lead the respondent to initiate iron chelation therapy at all)
to 7 (strongly leads to initiation of iron chelation therapy),
the mean score for this factor was 5.9. Other factors that
most led respondents to initiate iron chelation therapy
included serum ferritin levels >1,000 ng/mL (76%; mean
score, 6.0), candidacy for allogeneic stem cell transplanta-
tion (76%; mean score, 6.0), need to prevent organ
dysfunction (74%; mean score, 6.0), ≥2R B Cu n i t s
transfused per month (71%; mean score, 5.9), lifetime
transfusions of >20 RBC units (68%; mean score, 5.8), and
convenience of oral iron chelation therapy (67%; mean
score, 5.8).
The majority of respondents who prescribe iron chela-
tion therapy (92%) felt that a patient's serum ferritin
reaching a specific level was a marker at which to initiate
iron chelation therapy. The mean serum ferritin level at
which these respondents initiated iron chelation therapy
was 1,130 ng/mL. More than half of the respondents who
prescribe iron chelation therapy (56%) said that reaching a
certain number of blood units transfused was also a marker
(mean of 21 units). Other markers for initiating iron
chelation therapy included patients having received a
particular number of transfusions (mean of 18 transfusions;
41% of respondents who prescribe iron chelation therapy)
and the rate of increase of a patient's serum ferritin level
(33% of respondents who prescribe iron chelation therapy).
The strongest reasons for not initiating iron chelation
therapy were mostly related to poor patient prognosis and
patient age ≥85 years (Fig. 4). There were polarized
opinions regarding the importance of some of the reasons
for not initiating iron chelation therapy. For example, while
31% of respondents replied that a high-risk MDS classifi-
cation was a strong barrier in initiating iron chelation
therapy, 25% thought that this did not represent a
significant barrier. Similarly, while 28% said that expected
noncompliance was a strong barrier in initiating iron
chelation therapy, 23% thought this was a weak barrier.
Some of the reasons for not initiating iron chelation therapy
specifically related to the age of the patients being treated.
Older patient age was less of a reason to initiate iron
chelation therapy, and more of a reason not to, than younger
patient age.
Discussion
This survey was undertaken to better understand what
physicians perceive to be the key reasons for investigating
iron overload and managing iron overload when treating
1–2:
Not important
(at all)
34 5 6 7 :
Very important
2% 5% 20% 27% 46% 0%
Fig. 1 Subjective importance of
detection of iron overload
4.1
3.8
3.8
3.7
3.6
3.7
45
33 41 27
Lack of awareness of guidelines/recommendations 
for proper patient identification
38 32 30 Serum ferritin level not regularly monitored
Patient has a poor prognosis and pessimistic life expectancy
Not a barrier (at all)
(score 1–2) Score 3–5
(Strong) barrier
(score 6–7)
Percentage of physicians
Mean of
each barrier
12 34567
37
30
25
41
54
43
23
17
30
0 20 40 60 80 100
Lesser importance of iron overload in the 
context of overall MDS problems
Low priority of iron screening in MDS
Insufficient awareness about the risks of iron overload
in transfusion-dependent patients with MDS
23 34
Percentages in each row may not add up to 100% because of rounding
Fig. 2 The most important reservations about the detection of iron overload
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that they do not. The respondents who took part in MIDIS
were from multiple European countries, and the majority
were experienced physicians who appeared to have a keen
interest in the MDS therapy area. Over a quarter had more
than 25 years of experience working as physicians, and the
majority were actively involved in the diagnosis and
treatment of patients with MDS. The survey has the known
limitations of optional surveys; i.e., it was performed on
invitation at conferences or through e-mail alerts and
weblinks. Therefore, the survey may have been biased
toward respondents with an interest in MDS, and who may
have had a greater understanding of the management of
iron overload than the general population of hematologists.
Furthermore, MIDIS is not a representative sample of the
hematologists from each country, and the number of
respondents from each country does not accurately reflect
the proportion of that country's hematologists in Europe.
Nonetheless, the results of the survey provide a valuable
insight into the practices and beliefs of European physicians
treating transfusion-dependent patients with MDS. MIDIS
showed that approximately 70% of the respondents be-
lieved that detecting and treating iron overload were
important in patients with MDS. A total of 76% of
physicians felt that a serum ferritin level >1,000 ng/mL
was a relevant trigger to initiate iron chelation therapy.
Over 50% of the respondents monitored serum ferritin
levels quarterly as a surrogate marker for iron overload in
their patients, and overall, 38% of transfusion-dependent
patients with MDS were actively being treated for iron
overload with iron chelation therapy. In Europe, the
prevalence of MDS patients with Low/Int-1-risk MDS
(according to the IPSS) is reported to be approximately
70% [2], and 39–50% of those patients are transfusion-
dependent [13]. Therefore, approximately one third of
patients will be transfusion dependent and may be
candidates for iron chelation therapy, according to pub-
lished guidelines. The 38% response by the survey
respondents reflects their active iron chelation treatment
strategy. This is confirmed by a recent study showing that
41% of eligible patients with lower-risk MDS received iron
chelation therapy in clinical practice [14]. In all, the views
expressed in the survey are in line with a number of
international guidelines that recommend that serum ferritin
2% 7% 22% 31% 37%
1:
Not important 
[at all]
23 4 5 6 7 :  
Very important
0%
1%
Fig. 3 Subjective importance of
treating iron overload
5.8
4.9
4.7
4.6
4.3
4.2
4.1
Patient life expectancy is <1 year
Patient is aged ≥85 years
Patient life expectancy is <6 months
Expected non-compliance of the patient
Presence of comorbidity that
would limit prognosis
Health limitation caused by the kidney
High-risk MDS: e.g. High, Int-2 (IPSS) 
or RAEB, CMML (WHO)
Mean of
each barrier
25
23
15
13
15
7
44
49
58
53
44
31
21
31
28
27
34
41
50
72
20
Not a barrier (at all)
(score 1–2) Score 3–5
(Strong) barrier
(score 6–7)
1234567
Percentage of physicians
0 20 40 60 80 100
Percentages in each row may not add up to 100% because of rounding
Fig. 4 The most important reservations about initiating iron chelation therapy. RAEB refractory anemia with excess blasts, CMML chronic
myelomonocytic leukemia, WHO World Health Organization
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transfusion-dependent patients with MDS, and that iron
chelation therapy should be initiated when their serum
ferritin level reaches 1,000 ng/mL, depending on the
transfusion rate [4, 15–17]. Interestingly, fewer than a
quarter of the respondents considered concerns about
potential reductions in patient quality of life, the cost of
iron chelation therapy, and possible side effects of therapy
as strong reasons for not initiating treatment. Only 23%,
19%, and 11% of respondents, respectively, reported these
as barriers or strong barriers in initiating treatment.
Furthermore, the issue of potentially reduced quality of life
was polarized; the proportion of respondents who consid-
ered this to be a barrier was similar to the proportion of
those who did not (23% and 26%, respectively).
Participating physicians were asked whether considering
iron overload to be a lesser problem in patients with MDS
was a barrier in detecting iron overload. While 17% thought
this was a barrier or strong barrier, 30% were strongly
opposed to that view. This reflects the need for evidence-
based data regarding the role of iron chelation in MDS.
Serum ferritin is a well-known acute-phase reactant that
might overestimate the iron load in the presence of other
diseases, in particular infectious episodes [18]. More
accurate measurements of iron overload include liver and
heart magnetic resonance imaging; however, these are time-
consuming and not available at many centers. This may be
one reason why one third of MIDIS respondents said that
they believed that irregular monitoring of serum ferritin
levels was a strong barrier in detecting iron overload, while
38% thought that this did not prevent detection.
The survey respondents were reluctant to administer iron
chelation therapy to patients aged ≥85 years. It is difficult to
assess how transfusion dependence affects the overall
survival of this elderly patient population with Low- or Int-
1-risk MDS. Nonetheless, it is interesting to note that the
proportion of physicians opting against iron chelation
therapy for this population was higher than that of physicians
opting against treatment for patients with a life expectancy of
less than 1 year (Fig. 4). Instead, patient age of 55–64 years
was a strong reason for initiating iron chelation therapy.
In summary, this European survey has demonstrated that
physicians believe that iron overload is a relevant clinical
issue in transfusion-dependent patients with MDS that is
worthy of investigation and treatment. Concerns over age
and patient prognosis are key factors in the treatment
decisions taken by physicians. An ongoing, randomized
phase III trial in patients with Low- and Int-1-risk MDS on
iron overload in MDS will help to clarify the role of iron
chelation therapy in this patient population.
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